Skip to search formSkip to main contentSkip to account menu

Hsp90 Inhibitor HSP990

Known as: HSP990 
An orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp90 inhibitor Hsp990 binds to and… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Hsp90 inhibitor HSP990 in very low dose upregulates EAAT2 and exerts potent antiepileptic activity
Rationale: Dysfunction or reduced levels of EAAT2 have been documented in epilepsy. We previously demonstrated the antiepileptic… 
2015
2015
The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole.
The molecular chaperone heat shock protein 90 (Hsp90) is highly conserved in eukaryotes and facilitates the correct folding… 
2015
2015
A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
Background:Heat-shock protein 990 (HSP990) is a potent and selective synthetic small-molecule HSP90 inhibitor. The primary… 
2014
2014
Design, structure-activity relationship, and in vivo characterization of the development candidate NVP-HSP990.
Utilizing structure-based drug design, a novel dihydropyridopyrimidinone series which exhibited potent Hsp90 inhibition, good… 
Highly Cited
2013
Highly Cited
2013
Hsp90 inhibition protects against inherited retinal degeneration
The molecular chaperone Hsp90 is important for the functional maturation of many client proteins, and inhibitors are in clinical… 
2013
2013
Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
The heat shock protein (HSP) 90 chaperone machine involved in numerous oncogenic signaling pathways is over-expressed in cancer… 
Highly Cited
2012
Highly Cited
2012
Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
Purpose: Targeting Hsp90 has significant potential as a treatment for prostate cancer, but prototypical agents such as 17… 
Highly Cited
2012
Highly Cited
2012
The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo
A novel oral Hsp90 inhibitor, NVP-HSP990, has been developed and characterized in vitro and in vivo. In vitro, NVP-HSP990… 
2012
2012
Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.
BACKGROUND HSP90 inhibitors effectively reduce expression and activity levels of oncogenic survival proteins. However, their… 
Highly Cited
2011
Highly Cited
2011
Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma
The second most commonly diagnosed hematologic malignancy, multiple myeloma, affects predominantly older patients (>60s) and is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)